Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

WideCells anticipates closing £1.8mln share placing before end of the month

The company has taken a series of precautionary steps to conserve cash
WideCells anticipates closing £1.8mln share placing before end of the month
Widecells is a stem cell storage specialist

WideCells Group PLC (LON:WDC) has reconfirmed it has received commitments for its shares placing of at least £1.8mln, and anticipates being able to close the fundraiser before the end of the month.

The sum expected to be raised is in excess of the £1.5mln it requires to continue as a going concern.

WATCH: WideCells Group resumes trading - looks to close fundraise by end of month

However, Widecells cautioned: "Should the placing not complete in accordance with its terms by June 29, or alternative funding found, the group would not be able to continue trading as a going concern and would be obliged to cease operations which could include administration, receivership, liquidation or other insolvency proceedings."

As at June 8, the group was in overdraft, but has taken a number of steps to manage its current working capital.  

It has received £120,000 in directors' loans repayable next July; negotiated payment terms with existing trade creditors; agreed terms with its banks to extend its facilities; and revised its current growth plans downwards as well as cutting back on all discretionary expenditure to conserve cash.

WideCells also announced that the Live Market Bookbuild, which commenced on 10 May 2018, has now closed having received commitments to raise a further £513,000.

Accordingly , the firm added, it has received commitments representing a gross total of £2.036mln, including the monies committed under the bookbuild. 

It said directors of the group have participated in the bookbuild, collectively subscribing for 6,100,001 placing Shares at 3p per share for a total of £183,000 out of the £513,000 committed.

Build revenue portfolio

Widecells said the net proceeds of the placing “will be used to expand the group's core end-to-end stem cell services as it looks to build its revenue profile”.

João Andrade, WideCells Group CEO, commented:"With this Placing and Bookbuild receiving subscriptions to raise gross proceeds of £2 million, which includes continued support from institutional shareholders, we are delighted that investors continue to recognise the strong value fundamentals of our business, which we firmly believe in, as can be indicated through a number of Directors participating in this Placing. 

“Our focus now is to drive uptake of our innovative portfolio of stem cell services and ultimately build revenues as we embark on a new phase of growth.  We look forward to providing further updates in due course."

Trading in WideCells shares on AIM was restored this morning, with the stock changing hands at 3.15p each around 9.30am, , down 24% on the pre-suspension price of May 3.

-- Adds Live Market Bookbuild, details, share trading restoration --



View full WDC profile View Profile

WideCells Group Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use